These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11391566)

  • 21. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
    Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
    J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface.
    Lubman OY; Waksman G
    J Mol Biol; 2002 Feb; 316(2):291-304. PubMed ID: 11851339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Geometric diversity through permutation of backbone configuration in cyclic peptide libraries.
    Perlman ZE; Bock JE; Peterson JR; Lokey RS
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5329-34. PubMed ID: 16213707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pp60c-src mediates ERK activation/nuclear localization and PAI-1 gene expression in response to cellular deformation.
    Samarakoon R; Higgins PJ
    J Cell Physiol; 2003 Jun; 195(3):411-20. PubMed ID: 12704650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding affinity difference induced by the stereochemistry of the sulfoxide bridge of the cyclic peptide inhibitors of Grb2-SH2 domain: NMR studies for the structural origin.
    Shi YH; Song YL; Lin DH; Tan J; Roller PP; Li Q; Long YQ; Song GQ
    Biochem Biophys Res Commun; 2005 May; 330(4):1254-61. PubMed ID: 15823578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of dissociation constants of inhibitors binding to Src SH2 domain protein by non-covalent electrospray ionization mass spectrometry.
    Bligh SW; Haley T; Lowe PN
    J Mol Recognit; 2003; 16(3):139-48. PubMed ID: 12833569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preparation and characterization of potential antineoplastic agents].
    Orfi L; Wáczek F; Szabó M; Kövesdi I; Mészáros G; Idei M; Horváth A; Hollósy F; Mák M; Szegedi Z; Szende B; Kéri G; Noszál B
    Acta Pharm Hung; 1999 Jun; 69(3):115-22. PubMed ID: 10401154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
    Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK
    Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
    J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NMR solution structure of a potent cyclic nonapeptide inhibitor of ICAM-1-mediated leukocyte adhesion produced by homologous amino acid substitution.
    Sillerud LO; Burks EJ; Brown WM; Brown DC; Larson RS
    J Pept Res; 2004 Oct; 64(4):127-40. PubMed ID: 15357668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conformational and biochemical analysis of the cyclic peptides which modulate serine protease activity.
    Pakkala M; Jylhäsalmi A; Wu P; Leinonen J; Stenman UH; Santa H; Vepsäläinen J; Peräkylä M; Närvänen A
    J Pept Sci; 2004 Jul; 10(7):439-47. PubMed ID: 15298179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A molecular dynamics study of the interaction of D-peptide amyloid inhibitors with their target sequence reveals a potential inhibitory pharmacophore conformation.
    Esteras-Chopo A; Morra G; Moroni E; Serrano L; Lopez de la Paz M; Colombo G
    J Mol Biol; 2008 Oct; 383(1):266-80. PubMed ID: 18703072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Src protein tyrosine kinase activity is required for muscarinic receptor-mediated DNA synthesis and neurogenesis via ERK1/2 and c-AMP-responsive element-binding protein signaling in neural precursor cells.
    Zhao WQ; Alkon DL; Ma W
    J Neurosci Res; 2003 May; 72(3):334-42. PubMed ID: 12692900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-activity relationship study of CXCR4 antagonists bearing the cyclic pentapeptide scaffold: identification of the new pharmacophore.
    Tanaka T; Tsutsumi H; Nomura W; Tanabe Y; Ohashi N; Esaka A; Ochiai C; Sato J; Itotani K; Murakami T; Ohba K; Yamamoto N; Fujii N; Tamamura H
    Org Biomol Chem; 2008 Dec; 6(23):4374-7. PubMed ID: 19005596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src).
    Wang W; Ramdas L; Sun G; Ke S; Obeyesekere NU; Budde RJ; McMurray JS
    Biochemistry; 2000 May; 39(17):5221-8. PubMed ID: 10819990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibitors.
    Kumar A; Ye G; Wang Y; Lin X; Sun G; Parang K
    J Med Chem; 2006 Jun; 49(11):3395-401. PubMed ID: 16722659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
    Noronha G; Barrett K; Cao J; Dneprovskaia E; Fine R; Gong X; Gritzen C; Hood J; Kang X; Klebansky B; Li G; Liao W; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Soll R; Splittgerber U; Wrasidlo W; Zeng B; Zhao N; Zhou Y
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5546-50. PubMed ID: 16931012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. NMR studies of the RRsrc peptide, a tyrosine kinase substrate.
    Brockbank RL; Vogel HJ
    Biochem Cell Biol; 1997; 75(2):163-9. PubMed ID: 9250364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and biological evaluation of linear and cyclic phosphopeptide ligands of the N-terminal SH2 domain of protein tyrosine phosphatase SHP-1.
    Imhof D; Wieligmann K; Hampel K; Nothmann D; Zoda MS; Schmidt-Arras D; Zacharias M; Böhmer FD; Reissmann S
    J Med Chem; 2005 Mar; 48(5):1528-39. PubMed ID: 15743195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.